Introduction {#Sec1}
============

Immunoglobulin (IG) supplementation has been the standard treatment for patients with disorders of antibody production due to B cell or combined B and T cell abnormalities (PIDD) \[[@CR1]--[@CR5]\]. Regularly scheduled infusions of IG replace or supplement antibodies that decrease the risk of the serious bacterial and viral infections experienced by PIDD patients \[[@CR6]--[@CR8]\]. Although all available preparations of immune globulin provide sufficient antibodies to significantly decrease the frequency of infections in immunodeficient patients, infections continue to occur \[[@CR2], [@CR6]\]. Previous studies have suggested that some infections in antibody-deficient PIDD patients occur when the titer of protective antibody is inadequate \[[@CR9]--[@CR12]\]. While many of these reports have focused on bacterial pathogens, additional evidence supports the proposition that high titer anti-viral antibody preparations may provide advantages over conventional IG \[[@CR13], [@CR14]\].

Studies of an early RSV-IVIG, RespiGam®, in premature infants demonstrated the ability of this polyclonal anti-RSV hyperimmune globulin to reduce not only respiratory syncytial virus (RSV) infections but also other viral respiratory infections as well as otitis media \[[@CR15], [@CR16]\]. When this product was available, the American Academy of Pediatrics (AAP) stated that for children with severe immunodeficiencies receiving IG therapy during the winter months, physicians could consider the addition and/or substitution of the high titer RSV-IVIG for standard IG supplementation \[[@CR17]\]. These data suggested that a polyclonal anti-RSV hyperimmune globulin would confer enhanced protection from infection. Despite the successful use of this RSV-IVIG in premature infants, it was voluntarily withdrawn after the introduction of a monoclonal anti-RSV (Synagis®) antibody that could be administered intramuscularly rather than intravenously as was required for the polyclonal antibody \[[@CR14]\]. Consequently, a new IG formulation that meets all the standard criteria for treatment of PIDD (RI-002) was developed using plasma collected from individuals tested to have high titer anti-RSV antibodies \[[@CR18]\].

The present study was a prospective, open-label, non-randomized multicenter phase 3 study in the USA to evaluate the efficacy and safety of RI-002 in patients with PIDD. The primary objective was to evaluate the annualized acute serious bacterial infection rate. Secondary objectives including evaluation of missed days of work due to infection, unscheduled visits to the physician, days hospitalized due to infection as well as the safety and tolerability of RI-002 were also studied. Pharmacokinetic studies measured not only concentrations of total immune globulin, but also measured the concentrations of antibodies to RSV, cytomegalovirus (CMV), tetanus toxoid, *Haemophilus influenzae* type b (Hib), measles, and 13 serotypes of *Streptococcus pneumoniae*.

Methods {#Sec2}
=======

Study Product {#Sec3}
-------------

The investigational new drug used in this study (RI-002) was provided by ADMA Biologics (Ramsey, NJ).

RI-002 was manufactured from source plasma, obtained from approved donors, and screened for blood borne pathogens by binding assays and nucleic acid testing, which was purchased and obtained from domestic plasma donation centers licensed by US FDA and certified by Plasma Protein Therapeutic Association (PPTA). The plasma pool for each lot of RI-002 included sufficient plasma from donors with high neutralizing titers to RSV to meet a standardized value.

The manufacturing method included Cohn-Oncley fractionation followed by ion exchange chromatography followed by other downstream purification steps. The final product contains 100 ± 10 mg/mL protein. At least 96 % of the protein is human IgG with a monomer plus dimer content greater than 95 %. The distribution of IgG subclasses in the final product is similar to the distribution in the starting plasma.

The potency of the product meets 21 CFR 640.104 criteria for the required levels of antibody to measles, polio, and diphtheria in addition to having standardized elevated neutralizing titers to RSV. The RSV neutralizing titers for all lots used in the study were similar and have been found to be comparable to the former RespiGam® product.

Study Design {#Sec4}
------------

This was an open-label, phase III study to evaluate the efficacy, safety, and pharmacokinetics of subjects with documented PIDD (clinicaltrials.gov NCT01814800). Intravenous infusions were given at the study centers at doses of 300--800 mg/kg every 3 or 4 weeks for approximately 1 year. Dosing interval was determined by each subject's pre-study infusion schedule. Infusion rates began at 0.5 mg/kg/min and were incrementally increased every 15 min until reaching a maximum of 8 mg/kg/min. Doses of RI-002 were adjusted during the study to maintain minimum trough IgG concentrations \>500 mg/dL or at the investigator's discretion.

A subset of subjects participated in the PK portion of the study. PK data was analyzed for total IgG concentrations as well as specific antibody titers to RSV, CMV, tetanus, Hib, measles, and 13 serotypes of *S. pneumoniae*.

Study Subjects {#Sec5}
--------------

Eligible subjects were male and female aged 2--75 years, inclusive with a confirmed diagnosis of primary immunodeficiency. Prior to enrollment, subjects were required to have received IVIG infusions every 3 or 4 weeks at a dose that had not been changed by \>50 % of the mean dose on a mg/kg basis for ≥3 months. Subjects were excluded if they had a history of adverse reactions to blood or blood-derived products, selective IgA deficiency, and history of allergic reaction to products containing IgA or antibodies to IgA, abnormal liver function, deep vein thrombosis, hemolysis, or positive Coombs test or were pregnant or lactating.

Efficacy Evaluation {#Sec6}
-------------------

The primary efficacy endpoint was the demonstration of a serious bacterial infection (SBI) rate of less than 1.0 per person-year during the 12-month treatment with RI-002. Secondary efficacy endpoints included: the incidence of all infections of any kind, the number of days lost from work/school/usual activity due to infection and their treatment, the number of unscheduled visits to physician/ER due to infections, the time to resolution of infections, the number of hospitalizations and days of hospitalizations due to infections, the number of days of antibiotic therapy (prophylactic and treatment), the relationship among dose, trough level and risk of serious and non-serious infections, and trough total IgG and specific antibody levels.

Safety Evaluation {#Sec7}
-----------------

Subjects were monitored for adverse events (AEs) and serious adverse events (SAEs) during each infusion and between each visit using subject diaries. AEs were defined as any untoward medical occurrence whether or not the AE was determined to be product related. Subjects regularly completed a subject diary to capture data between study infusions. Subject diaries were used to capture the incidence and duration of infections (SBIs and other infections), use of antibiotics, sick days (missed work or school), unscheduled doctor or hospital visits due to infection, and the incidence of adverse events. These data were reviewed with study personnel at each study visit to confirm their accuracy and completeness. Temporally associated AEs (TAAEs) were adverse events occurring within 72 h of RI-002 infusion. Safety endpoints included the incidence of TAAEs, SAEs, and related SAEs, discontinuation of study treatment, and PIDD related deaths, infusion site reactions, change in vital signs before or after infusion, proportion of infusions with one or TAAEs, and changes in laboratory values.

Pharmacokinetic Evaluation {#Sec8}
--------------------------

The blood samples for PK analysis were obtained beginning after Infusion 7 or Infusion 9 in order to allow for wash out of the previous IG product. Scheduled sampling times were as follows: immediately prior to the infusion, end of the infusion, 60 min, 2 h, 24 h, 48 h, 4 days, 7 days, 14 days, 21 days, and 28 days post-infusion. All PK parameters were calculated using non-compartmental analysis. Only those plasma concentrations equal to or greater than the validated lower limit of quantitation of the individual antibody assays were used in the analysis. Actual sampling times were used in all pharmacokinetic analyses. Per protocol times were used to calculate mean plasma concentrations for graphical displays. Calculated PK parameters included: elimination constant (K), elimination half-life (t½), area under the curve (AUC~(0-t)~) over the 21 or 28-day dosing interval, total plasma clearance (CL), and volume of distribution (Vz). Levels of specific antibody to CMV, tetanus, Hib, measles, and RSV were determined at each time point.

Statistical Analysis {#Sec9}
--------------------

The Intent-To-Treat (ITT) population included all screened subjects who fulfilled eligibility criteria for RI-002 treatment. All ITT subjects who received at least one RI-002 infusion in the study (referenced to as mITT) were the primary population for efficacy and safety analyses. The PK population includes all mITT subjects who enrolled to participate in the PK portion of the study and who had sufficient plasma samples drawn to derive PK parameters.

Descriptive statistics were provided for the overall population and by treatment regimen (*n*, mean, SD, minimum, median, and maximum for continuous variables and counts and percentages for categorical variables). Infections were identified based on reported treatment emergent adverse events that were mapped to MedDRA 'Infection and Infestations' System Organ Class. The concomitant medications records were used to identify all antibiotic medications based on the WHO Drug Coding of ATC level, route and indication. Annualized rate (per person per year) was calculated by total episodes (e.g., total infection events) or total days (e.g., days lost due to infection) divided by total person-years. The one-sided 95 % upper bound for annualized rate was estimated from a general linear model for Poisson distribution with only the intercept parameter. Quartiles and mean days to resolution of infections were estimated using Kaplan-Meier estimates.

The two-sided 90 % confidence intervals were calculated using normal approximation with a continuity correction for proportion of infusions with ≥ 1 TAAEs.

Results {#Sec10}
=======

Subject Demographics {#Sec11}
--------------------

A total of 75 subjects were screened and 59 subjects, 28 males and 31 females, were enrolled and received at least 1 RI-002 infusion (mITT population). The majority of study subjects were Caucasian (98.3 %), average age was 41.8 years ranging from 3 to 73 years. The study included 48 adult subjects (\>16 years of age) and 11 pediatric subjects. The most common PIDD type was common variable immunodeficiency (CVID) in 45 subjects (76.3 % of the subjects). Mean time from diagnosis to study enrollment was 8.66 years (ranged from 0.3 to 32.9 years). Demographic characteristics were similar between the two regimens (Table [1](#Tab1){ref-type="table"}).Table 1Summary of demographic data for mITT populationTotal\
(*N* = 59)3-Week cycle\
(*N* = 19)4-Week cycle\
(*N* = 40)Age, mean (SE)41.8 (2.84)38.6 (4.94)43.3 (3.48) Subjects ≤16 years, *n*1138 Subjects 17 to 64 years, *n*371225Subjects ≥65 years, *n*1147PIDD diagnosis, *n* (%) CVID46 (77.9)17 (89.5)29 (72.5) X-linked Agammaglobulinemia6 (10.2)06 (15.0) Antibody deficiencies7 (11.9)2 (10.5)5 (12.5)Years since diagnosis, mean (SE)8.66 (1.1)6.87 (1.4)9.51 (1.5) Median (range)5.68 (0.3, 32.9)5.13 (0.5, 21.7)5.82 (0.3, 32.9)

Efficacy {#Sec12}
--------

RI-002 was efficacious in the treatment of subjects with PIDD aged 3 to 74 years, over a 1-year period. The efficacy of RI-002 (Table [2](#Tab2){ref-type="table"}) was demonstrated by the absence of any SBIs in the study population. The observed incidence of zero (0) SBIs in 55.88 subject years (20,396 total study days) of treatment resulted in a SBI rate below the criteria of \<1.0 SBI per subject per year set by FDA. Other key efficacy secondary endpoints included lost days from work/school/daycare due to infection (1.66 days per subject per year), unscheduled emergency room/medical visits due to infection (0.966 visits per subject per year), and hospitalizations due to infection (0.018 hospitalizations per subject per year).Table 2Summary of Annualized rates for infections, antibiotics use, days lost for work/school/daycare, unscheduled visits, and hospitalizationsTotal3-Week cycle4-Week cycleNumber of mITT Subjects591940Total number subject-years55.917.338.6Infections Number of Serious acute bacterial infections (SBIs)000 Rate of SBIs per person per years (one-sided 99 % upper bound)0.000 (\<1.0)0.000 (\<1.0)0.000 (\<1.0) Total infections of any kind/seriousness19262130 Infections per subject per year (one-sided 95 % upper bound)3.436 (3.869)3.584 (4.417)3.370 (3.893)Antibiotic use for therapy Number of subjects, *n* (%)37 (62.7)12 (63.2)25 (62.5) Days per subject per year32.941.229.2Days off school/work/day care due to infection Number of Subjects, *n* (%)23 (39.0)7 (36.8)16 (40.0) Total days932766 Days per subject per year (one-sided 95 % upper bound)1.66 (1.97)1.56 (2.14)1.71 (2.09)Unscheduled visits to the ER and physician due to infection Number of subjects, *n* (%)24 (40.7)9 (47.4)15 (37.5) Total days541836 Days per subject per year (one-sided 95 % upper bound)0.97 (1.21)1.04 (1.53)0.93 (1.23)Hospitalization due to infection Number of subjects, *n* (%)1 (1.7)01 (2.5) Number of days505 Hospitalizations per subject per year0.01800.026

Analysis of trough concentrations of IgG and specific antibodies demonstrated that administration of RI-002 at doses of 284--1008 mg/kg every 3 or 4 weeks generally maintained concentrations similar to those present at baseline. Trough RSV titers, however, were an exception to this observation with levels increasing after the first RI-002 infusion and remaining elevated throughout the study. Increase in antibody levels to all pathogens tested were observed in subjects who received RI-002 and those subjects who received doses of ≥500 mg/kg demonstrated even higher specific antibody levels to all pathogens compared to those receiving doses ≤ 500 mg/kg.

Although this study was not powered to identify differences in safety or efficacy between 3 and 4-week cycles, subjects dosed with RI-002 on a 3-week cycle were observed to have higher trough IgG concentrations compared to subjects on a 4-week cycle but there was no evidence suggesting a difference in efficacy or safety outcomes based on the treatment cycle. Both treatment cycles were successful in maintaining trough IgG concentrations well above the targeted threshold of 500 mg/dL, with mean IgG trough levels ranging from 1051.6 to 1194.9 mg/dL for subjects on a 3-week cycle, and 913.3 to 978.5 mg/dL for subjects on a 4-week cycle.

Pharmacokinetics {#Sec13}
----------------

Thirty subjects, 20 subjects on a 4-week infusion cycle and 10 subjects on a 3-week infusion cycle, participated in the PK portion of the study. Administration of RI-002 with either regimen resulted in increases in IgG and in CMV, tetanus, Hib, measles, RSV, and *S. pneumoniae* serotype antibodies with the greatest increase in C~max~ observed in antibodies to RSV. There was a 5.47-fold increase in the titer of anti-RSV neutralizing antibody immediately after infusion of the IVIG and a 6.79-fold increase in those subjects who received greater than 500 mg/kg (Table [3](#Tab3){ref-type="table"}). In this calculation, baseline was that value of anti-RSV measured immediately prior to entry into the trial. Figure [1](#Fig1){ref-type="fig"} shows the pharmacokinetics of anti-RSV antibodies, and in this situation, baseline was the value of anti-RSV that was measured in the subjects enrolled in the PK portion of the study immediately prior to infusion of the seventh or ninth dose of IVIG. RI-002 is manufactured to contain standardized, elevated levels of neutralizing antibodies to RSV, and all lots are tested for release potency for RSV antibody levels. There was no apparent difference between groups in the mean plasma concentrations of IgG and the mean values for C~max~ despite a slightly larger AUC over the dosing interval due to the 7-day longer period. Although the mean values for t½ should be considered as qualitative because of the period of time over which λz was measured, they are consistent with literature values for the t½ of IgG.Table 3Maximum observed neutralizing antibodies to RSV (Cmax) post-infusion and fold change from baseline -- PK evaluable set (*N* = 30)Dose groupStatisticsBaselineCmaxFold change (Cmax/baseline)All doses*n*293029Mean (SE)1260.00 (272.885)4770.20 (392.025)5.47 (0.534)95 % CI701.02, 1818.983968.42, 5571.984.37, 6.56Dose \< 500 mg/kg*n*151515Mean (SE)1532.27 (499.761)4145.93 (529.355)4.23 (0.596)95 % CI460.39, 2604.153010.58, 5281.292.95, 5.51Dose≥500 mg/kg*n*141514Mean (SE)968.29 (177.181)5394.47 (548.453)6.79 (0.776)95 % CI585.51, 1351.064218.15, 6570.785.11, 8.47 Fig. 1Neutralizing antibodies to RSV before and post-infusion by dose and nominal time point post infusion -- PK evaluable set (*N* = 30)

Although there was a range of RI-002 doses within each group, there was no apparent relationship between AUC over the dosing interval and either total dose or weight adjusted dose for either cohort (Table [4](#Tab4){ref-type="table"}). Taken as a whole, the increases in the RSV, CMV, tetanus, Hib, measles, and *S. pneumoniae* antibodies were not affected by the treatment intervals used in this study. The mean values for all antibodies measured at baseline were comparable to the pre-infusion titers for both cohorts, and the maximum titers were higher than the baseline and pre-infusion titers. There did not appear to be a difference in exposure to IgG as a function of sex or age group. Analysis of baseline corrected plasma IgG concentrations resulted in comparisons between the 3 and 4-week cycle cohorts that were comparable to those using plasma concentrations without baseline correction.Table 4Total IgG pharmacokinetic parameter estimates (PK population)Statistic3-Week cycle (*N* = 10)4-Week cycle (*N* = 20)Mean ± SD (*n*)CV%Mean ± SD (*n*)CV%C~max~ (mg/dL)2427 ± 452 (10)18.632227 ± 584 (20)26.21C~min~ (mg/dL)1152 ± 308 (10)26.73954 ± 245 (20)25.65T~max~ (h)^a^2.93 \[1.80,4.52\] (10)NA2.78 \[1.43,99.08\] (20)NAAUC~tau~ (day mg/dL)32,128 ± 7020 (10)21.8535,905 ± 9351 (20)26.04t½ (day)28.47 ± 4.38 (6)15.3839.70 ± 11.57 (13)29.13CL (mL/kg/day)1.68 ± 0.43 (10)25.421.47 ± 0.50 (20)33.63V~ss~ (dL/kg)76.79 ± 13.45 (6)17.5289.57 ± 26.16 (13)29.21*AUC* ~tau~ steady-state area under the plasma concentration versus time curve with tau=dosing interval, *CL* total body clearance, *C* ~ma*x*~ maximum concentration, *C* ~min~ minimum concentration, *CV* coefficient of variation, *n* number of subjects, *NA* not applicable, *SD* standard deviation, *T* ~max~ time of maximum concentration, *t½* terminal half-life, *V* ~ss~ volume of distribution steady-state^a^ Units median \[range\] (*n*)

Safety {#Sec14}
------

RI-002 was well tolerated in this study. The proportion of study infusions with a TAAE was 0.142 with an upper one-sided 95 % confidence limit of 0.164, indicating that the study met the target (\<0.40) for this safety endpoint. During the study, 43 (72.9 %) subjects experienced at least one TAAE, and TAAEs were experienced during 113 (14.2 %) study infusions (Table [5](#Tab5){ref-type="table"}).Table 5Summary of temporally associated AEs (TAAEs)Total3-Week cycle4-Week cycleTotal number of subjects591940Total number of infusions793294499Number of infusions with ≥ 1 TAAEs1133677Total number of TAAEs15847111Mean number of TAAEs per infusion0.1990.1600.222Proportion of infusions with ≥ 1 TAAEs (one-sided 95 % upper limit)0.142 (0.164)0.122 (0.156)0.154 (0.182)Subjects with ≥ 1 TAAE, *n* (%) Within 1 h28 (47.5)7 (36.8)21 (52.5) Within 24 h40 (67.8)13 (68.4)27 (67.5) Within 72 h43 (72.9)15 (78.9)28 (70.0)Subjects with ≥ 1 study drug-related TAAE, *n* (%) Within 1 h14 (23.7)5 (26.3)9 (22.5) Within 24 h21 (35.6)7 (36.8)14 (35.0) Within 72 h21 (35.6)7 (36.8)14 (35.0)TAAEs reported by ≥ 5 % total subjects, *n* (%) Headache14 (23.7)3 (15.8)11 (27.5) Sinusitis6 (10.2)2 (10.5)4 (10.0) Nausea5 (8.5)1 (5.3)4 (10.0) Acute sinusitis4 (6.8)1 (5.3)3 (7.5) Fatigue4 (6.8)2 (10.5)2 (5.0) Muscle spasms4 (6.8)1 (5.3)3 (7.5) Adverse drug reaction3 (5.1)03 (7.5) Bronchitis3 (5.1)03 (7.5) Diarrhea3 (5.1)1 (5.3)2 (5.0) Epistaxis3 (5.1)03 (7.5) Myalgia3 (5.1)2 (10.5)1 (2.5) Oropharyngeal pain3 (5.1)03 (7.5) Pain in extremity3 (5.1)03 (7.5) Pruritus3 (5.1)03 (7.5)

There were 793 infusions administered during the study, with an average of 13.4 infusions administered per subject. Of 793 study infusions, one was not completed as planned, and two infusions (in 2 different subjects) were interrupted due to an AE and completed on the next day. The mean (SE) planned weight adjusted dose of RI-002 administered during this study was 505.2 (4.84) mg/kg, with a range of 284 to 1008 mg/kg.

The majority of subjects in this study did not experience any infusion-related AEs or complications. Study infusions were generally well tolerated with 95.8 % of infusions administered at the maximum allowed infusion rate of 8 mg/kg/min RI-002 infusion rates ranged from 0.5 to 13.3 mg/kg/min during the study. The use of pre-medication was limited to seven study infusions (out of a total of 793 total infusions) in seven subjects (0.009 %).

No serious bacterial infections occurred during the study. A total of 618 treatment emergent AEs (TEAEs) were experienced by 58 subjects (98.3 %) during the course of this study (Table [6](#Tab6){ref-type="table"}). The most frequently reported TEAEs, regardless of relationship to study drug, included: headache, sinusitis, diarrhea, viral gastroenteritis, nasopharyngitis, and upper respiratory tract infection. A total of 55 TEAEs were determined to be study drug related in 26 (44.1 %) study subjects. The most frequently reported study drug-related TEAE was headache.Table 6Summary of treatment emergent adverse eventsCategoryTotal (*N* = 59)3-Week cycle (*N* = 19)4-Week Cycle (*N* = 40)No.*n* (%)No.*n* (%)No.*n* (%)Subjects with ≥ 1 TEAE61858 (98.3)18018 (94.7)43840 (100) Subjects with ≥ 1 Mild TEAE41155 (93.2)11918 (94.7)29237 (92.5) Subjects with ≥ 1 Moderate TEAE18648 (81.4)5917 (89.5)12731 (77.5) Subjects with ≥ 1 Severe TEAE219 (15.3)22 (10.5)197 (17.5)Subjects with ≥ 1 study drug related TEAE5526 (44.1)2210 (52.6)3316 (40)Subjects with ≥ 1 related and severe TEAE32 (3.4)11 (5.3)21 (2.5)Subjects with ≥ 1 SAE22 (3.4)0022 (5.0)Subjects withdrawals due to an AE22 (3.4)0022 (5.0)Deaths000000TEAE occurred ≥ 10 % total subjects Headache4222 (37.3)136 (31.6)2916 (40.0) Sinusitis3116 (27.1)115 (26.3)2011 (27.5) Diarrhea1614 (23.7)33 (15.8)1311 (27.5) Gastroenteritis viral1613 (22.0)54 (21.1)119 (22.5) Nasopharyngitis2313 (22.0)116 (31.6)127 (17.5) Upper respiratory tract infection1513 (22.0)54 (21.1)109 (22.5) Bronchitis1412 (20.3)11 (5.3)1311 (27.5) Nausea1712 (20.3)22 (10.5)1510 (25.0)Study drug-related TEAEs occurring in \> 20 % of total subjects Headache108 (13.6)33 (15.8)75 (12.5)No. = total number of events

There were no SAEs reported during the trial attributable to the study drug. Two serious adverse events (SAEs) were reported, one instance each of post-operative wound infection and migraine. Neither SAE was associated with the study drug; each event was experienced as a single occurrence in a single subject.

There was a low incidence of adverse infusion reactions, with a total of 31 events experienced by 18 subjects (30.5 %) during 29 infusions (3.7 %). The most frequently reported events included headache and myalgia. A total of four infusion site reactions were reported in this study in two subjects. The infusion site reactions reported included infusion site extravasation and infusion site pain. There was no evidence of a trend towards significant changes in any of the laboratory assessments during treatment with study medication. End of study laboratory assessments were generally similar to screening assessments, with no trends noted. There was no laboratory evidence of any instances of a thrombotic event, acute renal failure, hemolysis event, viral transmission, aseptic meningitis, or transfusion-related acute lung injury.

Discussion {#Sec15}
==========

Among the viral infections that cause substantial morbidity, respiratory syncytial virus is a particular problem, especially in patients with coexistent pulmonary disease \[[@CR19], [@CR20]\]. In 1996, an anti-RSV hyper-immune globulin product, RSV-IVIG (RespiGam®), was approved for the prevention of severe respiratory syncytial virus infection in premature infants whose gestational age was less than 32 weeks. Studies suggested that RSV-IVIG reduced disease severity in infants who became infected with RSV, shortening hospital stays compared to age-matched controls \[[@CR15], [@CR16], [@CR21]\]. Despite these beneficial effects, RSV-IVIG was voluntarily removed from the market by the manufacturer in favor of an intramuscularly administrated monoclonal anti-RSV antibody palivizumab (Synagis®). There are no direct head to head clinical studies comparing the efficacy of RSV-IVIG to palivizumab \[[@CR17]\]. While both appear comparable in their ability to prevent RSV infections in low birth weight infants, there appear to be certain clinical advantages of the polyclonal antibody \[[@CR17]\]. In the PREVENT study, not only was RSV-IVIG able to prevent RSV infections but it also reduced the incidence of other, non-RSV-related upper respiratory diseases \[[@CR15]\]. Another study demonstrated that high-risk infants receiving RSV-IVIG had a statistically significant reduction in the overall frequency of otitis media compared with placebo-treated subjects, also suggesting that polyclonal antibody activity to other pathogens may have contributed to this reduction observed in the incidence of otitis media \[[@CR21]\]. Interestingly, in the current study, there was only one single reported case of otitis media, an exceedingly low incidence for this population of subjects in the study. Recently published studies in the cotton rat demonstrated that RI-002 can not only reduce the viral load in normal and immune suppressed cotton rats that have been infected with RSV, but that it can dramatically reverse the intense inflammatory changes that are observed in their pulmonary tissue \[[@CR22]\].

Because of the historical data suggesting the potential value of a polyclonal anti-RSV, IG product for the immune-compromised patient population, a new Ig formulation was developed. The new product, RI-002, is an IVIG that is manufactured and standardized to contain elevated levels of anti-RSV neutralizing antibody and, in this regard, is comparable to RespiGam® \[[@CR22]--[@CR24]\]. However, this new product has the added advantage that it is manufactured to comply with the FDA guidance for IG products for the treatment of patients with PIDD \[[@CR18]\]. Similar to other IGs, this IVIG (RI-002) was made from plasma collected from more than 1000 plasma donors and was manufactured using an FDA-approved fractionation and purification process \[[@CR25], [@CR26]\]. Unlike other IGs, the plasma that was used to produce RI-002 was collected from donors who were identified and selected to have high neutralizing antibody titers to RSV. The selection was based on testing results obtained utilizing a validated RSV live-virus microneutralization assay. There was as great as a 6.79-fold increase in the levels of anti-RSV neutralizing antibody that was measured in subjects who were on the dosing regimen of greater than 500 mg/kg. Interestingly, the lots of IVIG produced from RSV hyperimmune donors were also found to have significantly elevated antibody titers to other respiratory viruses (parainfluenza type 1 and 3, influenza, coronavirus, and metapneumovirus) as compared to ten other commercial lots of IG \[[@CR27]\]. This preparation of RI-002, therefore, can be regarded as having a unique antibody profile for multiple respiratory viruses that differentiates it from other commercially available IGs. Viewed in the context of data from other IG trials, there are many of the secondary efficacy endpoints, for example number of days missed from work/school/daycare (1.66 per subject per year), hospitalization per subject per year (0.018), and unscheduled visits to the physician or emergency room (0.72 per subject per year) compared favorably to these published trials \[[@CR25], [@CR28]--[@CR30]\]. This study demonstrated excellent outcomes that might reflect the unique antibody profile of RI-002.

The efficacy of RI-002 is likely the result of the maintenance of stable IgG trough levels as well as specific antibody levels throughout the study conferring the expected protective effects of IG therapy. The pharmacokinetic properties of RI-002 were comparable to previous reports of IVIG preparations. All subjects maintained average trough levels of serum Ig of approximately 1000 mg/kg. There were significant post-infusion increases in all of the specific antibody titers measured with a greater than 6-fold increase seen in the concentration of RSV-neutralizing antibody immediately post-infusion in patients receiving greater than 500 mg/kg of IG.

There were no acute serious bacterial infections reported. The single infection that required hospitalization was believed to be secondary to a cat scratch that infected a recovering, post-operative, shoulder joint repair wound. That subject was non-compliant and missed his regularly scheduled dose of RI-002.

RI-002 was safe and well tolerated. The rates of temporally associated and treatment associated adverse events were well within the FDA guidance and comparable to the rates of adverse events that have occurred in studies of other IVIG products. Infusions were completed without interruption, discontinuation or rate reduction in 790 of 793 (99.6 %) infusions.

Two subjects each reported one SAE (post-operative wound infection and migraine) during this study, and neither was associated with study drug. The subject with the post-operative wound infection SAE discontinued from the study whereas the subject with SAE of migraine completed the study. One subject had an adverse drug reaction and discontinued from the study. Three other discontinuations were due to other causes (one subject became pregnant, one subject was relocated, and 1 was discontinued due to sponsor because of subject non-compliance).

Conclusions {#Sec16}
===========

RI-002 is a safe, well-tolerated, highly effective immunoglobulin replacement for PIDD, manufactured with a unique antibody profile from a donor population tested to have elevated anti-RSV-neutralizing antibody titers. The unexpectedly low rate of infection-related outcomes suggests that the unique, anti-viral antibody profile of RI-002 may be important in the prevention of infections in PIDD subjects and raises novel questions about the role of viral infections in the pathogenesis of the infectious complications of PIDD. Since it has been reported that pulmonary viral infections are often the antecedent to bacterial pulmonary infections, it is tempting to speculate that an IVIG that has high titer antibodies to viruses may also have an impact on reducing the incidence of bacterial infections.
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